American Capital sells portfolio company for proceeds of $210M

• Sold is SPL Acquisition Corp. to Shenzhen Hepalink Pharmaceutical. American Capital (NASDAQ:ACAS +0.9%) realized a 15% compounded annual rate of return over the seven-plus year life of its debt and equity investments in the company.
• Press release